Zusammenfassung
Die arterielle Hypertonie ist die häufigste Herz-Kreislauf-Erkrankung überhaupt, und sie ist eine Alterskrankheit. In den westlichen Industrienationen sind die älteren Menschen (>65 Jahre) die am stärksten wachsende Bevölkerungsgruppe.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
1 MEL 100 = melphalan 100 mg/m2; MPR-R = melphalanprednisone-lenalidomide gefolgt von lenalidomide; MPT = melphalan-prednisonethalidomide; Rd = lenalidomide plus niedrig dosiert Dexamethason; Vd = bortezomib + Dexamethason; VCD = bortezomib Cyclophosphamide - Dexamethason; VMP = bortezomib-melphalan Prednisone; VMPT-VT = bortezomibmelphalan-prednisonethalidomide gefolgt von bortezomib-thalidomide; VRD = bortezomib-lenalidomide Dexamethason.
Literatur
Alderman MH (1999) A new model of risk: implications of increasing pulse pressure and systolic blood pressure on cardiovascular disease. J Hypertens Suppl 17(5):S25–S28
Aronow WS, Fleg JL, Pepine CJ et al. (2011) ACCF/AHA 2011 Expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists and European Society of Hypertension. J Am Coll Cardiol 57:2037–114
Beckett NS, Peters R, Fletcher AE et al. (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1898
Boersma E, Keil U, De Bacquer D et al. (2003) Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 21:1831–1840
Conlin PR, Gerth WC, Fox J et al. (2001) Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 23:1999–2010
Duprez DA, Munger MA, Botha J et al. (2010) Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens 24:600–8
Düsing R (2001) Adverse events, compliance, and changes in therapy. Curr Hypertens Rep 3:488–492
ESC Pocket Guidelines 2013 (2014) Leitlinien für das Management der arteriellen Hypertonie, herausgegeben von der Deutschen Gesellschaft für Kardiologie - Herz und Kreislaufforschung e.V. und der Deutschen Hochdruckliga e.V., http://leitlinien.dgk.org/files/2014_Pocket-Leitlinien_Arterielle_Hypertonie.pdf, gesehen 19.5.2015
Hasford J, Schröder-Bernhardi D, Rottenkolber M et al. (2000) Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol 63:1055–1061
Hense HW (2000) MONICA Study: Epidemiology of arterial hypertension and implications for its prevention. 10-year results of the MONICA Study Augsburg). Dtsch Med Wochenschr 125:1397–1402
Insua JT, Sacks HS, Lau TS et al. (1994) Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 121:355–362
Kotseva K, Wood D, De Bacquer G et al.; EUROASPIRE investigators (2015) EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol February 16, 2015 2047487315569401
Lawes C, Vander Hoorn S, Rodgers A (2008) for the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 371:1513–1518
Liu X, Rodriguez CJ, Wang K (2015) Prevalence and trends of isolated systolic hypertension among untreated adults in the United States. J Am Soc Hypertens 9:197–205
Löwel H, Kuch B, Meisinger C et al. A (2001) Koronarpatient im Alter – epidemiologische Sicht. Herzmedizin 18:110–119
Mancia G, Fagard R, Narkiewicz K et al. (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 31:1281–1357
Milchak JL, Carter BL, Ardery G et al. (2008) Physician adherence to blood pressure guidelines and its effect on seniors. Pharmacotherapy 28(7):843–851
Plouin PF, Rossignol P, Bobrie G (2006) Hypertension in the elderly. Bull Acad Natl Med 190:793–805
Robert-Koch-Institut Epidemiologisches Bulletin Nr. 5, S. 33–36, 2. Februar 2015
Staessen JA, Thijs L, Fagard R et al. (1999) Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 282:539–546
Sytkowski PA, D‘Agostino RB, Belanger AJ et al. (1996) Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 93:697–703
Wehling M (2013) Morbus diureticus in the elderly: epidemic overuse of a widely applied group of drugs. J Am Med Dir Assoc 14:437–42
Wittchen HU, Glaesmer H, März W (2005) Cardiovascular risk factors in primary care: methods and baseline prevalence rates – the DETECT program. Curr Med Res Opin 21:619–630
Literatur
Ahmed A, Husain A, Love TE et al. (2006) Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27:1431–1439
Brunner-La Rocca HP, Buser PT, Schindler R et al., TIME-CHF-Investigators (2006) Management of elderly patients with congestive heart failure – design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 151(5):949–955
Bulpitt CJ (2005) Secondary prevention of coronary heart disease in the elderly. Heart 91:396–400
Cowie MR, Wood DA, Coats AJ et al. (1999) Incidence and aetiology of heart failure; a population-based study. Eur Heart J 20(6):421–428
Deedwania PC, Gottlieb S, Ghali JK et al. (2004) Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol XL in elderly patients with heart failure. Eur Heart J 25:1300–1309
ESC Pocket Guidelines (2013) Herzinsuffizienz - Leitlinien für die Diagnose und Behandlung der akuten und chronischen Herzinsuffizienz. Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. http://leitlinien.dgk.org/2013/pocket-leitlinie-herzinsuffizienz-update-2012/ gesehen 20.5.2015
Flather MD, Yusuf S, Kober L et al. (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355:1575–1581
Flather MD, Shibata MC, Coats AJ et al. (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26(3):215–225
Ho KKL, Pinsky JL, Kannel WB et al. (1993) The epidemiology of heart failure – the Framingham Study. J Am Coll Cardiol 22:A6–A13
Hunt SA, Abraham WT, Chin MH et al. (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154–e235
Kannel WB, Belanger AJ (1991) Epidemiology of heart failure. Am Heart J 121:951–957
Leibundgut G von, Pfisterer M, Brunner-La Rocca HP (2007) Drug treatment of chronic heart failure in the elderly. Drugs Aging 24(12):991–1006
Swedberg K, Komajda M, Böhm M et al., SHIFT Investigators (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875–8
Turakhia MP, Santangeli P, Winkelmayer WC et al. (2014) Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol 64:660–8
Yancy CW, Jessup M, Bozkurt B et al. (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:e147–239
Zuccalà G, Onder G, Marzetti E et al. (2005) Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J 26(3):226–233
Literatur
Jauch EC, Saver JL, Adams HP Jr et al. (2013) Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 44:870–947
Adams RJ, Albers G, Alberts MJ et al. (2008) Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39:1647–1652
Alpérovitch A, Kurth T, Bertrand M et al. (2015) Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study. BMJ 350:h2335
Amarenco P, Bogousslavsky J, Callahan A 3rd et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549–559
Aronow WS, Ahn C (1996) Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol 77:864–866
Bach RG, Cannon CP, Weintraub WS et al. (2005) The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 141(3):186–195
Baigent C, Keech A, Kearney PM et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278
Bangalore S, Steg G, Deedwania P et al. (2012) Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308:1340–1349
Boersma E, Harrington RA, Moliterno DJ et al. (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syn-dromes: a meta-analysis of all major randomised clinical trials. Lancet 359(9302):189–198
Cholesterol Treatment Trialists’ CTT Collaboration, Baigent C, Blackwell L et al. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 376:1670–1681
COMMIT Collaborative Group (2005) Early intravenous then oral metoprolol in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 366:1622–1632
Döser S, März W, Reinecke MF et al. (2004) Empfehlungen zur Statintherapie im Alter: Daten und Consensus. Internist (Berl) 45(9):1053–1062
Gesundheitsberichterstattung des Bundes (2015) Daten zu Herzinfarkten in der Region Augsburg. Mortalität, Morbidität, Letalität, Vorerkrankungen, medizinische Versorgung. http://www.gbebund.de/gbe10/ergebnisse.prc_tab?fid=6770&suchstring=Gesundheitsberichterstattung_des_Bundes_%282009%29_Daten_zu_Herzinfarkten_in_der_Region_Augsburg&query_id=&sprache=D&fund_typ=TAB&methode=1&vt=1&verwandte=1&page_ret=0&seite=1&p_lfd_nr=12&p_news=&p_sprachkz=D&p_uid=gast&p_aid=4373512&hlp_nr=3&p_janein=J. Gesehen 20.05.2015
Grundy SM, Cleeman JI, Merz CNB et al. (2004) Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 110:227–239
Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 45:2160–236
Krumholz HM, Radford MJ, Ellerbeck EF et al. (1995) Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. Circulation 92(10):2841–2847
Kyriakides ZS, Kourouklis S, Kontaras K (2007) Acute coronary syndromes in the elderly. Drugs Aging 24(11):901–912
Lenderink T, Boersma E, Gitt AK et al. (2006) Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than nonusers: a report from the first Euro Heart Survey on acute coronary syndromes. Eur Heart J 27(15):1799–1804
Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22
Fibrinolytic Therapy Trialists‘ (FTT) Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343(8893):311–322
Keaney JF Jr, Curfman GD, Jarcho JA. (2014) A pragmatic view of the new cholesterol treatment guidelines. N Engl J Med 370:275–8
Petersen S, Peto V, Scarborough P et al. (2005) Coronary heart disease statistics. London, British Heart Foundation
Schuler J, Maier B, Behrens S et al. (2006) Present treatment of acute myocardial infarction in patients over 75 years–data from the Berlin Myocardial Infarction Registry (BHIR). Clin Res Cardiol 95(7):360–367
Shepherd J, Blauw GJ, Murphy MB et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623–1630
Smith SC, Benjamin EJ, Bonow RO et al. (2011) AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Circulation 124:2458–2473
Stone NJ, Robinson J, Lichtenstein AH et al. (2014) ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl 2):S1–45
Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW et al. (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28(13):1598–1660
The TIME Investigators (2001) Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 358:951–957
Literatur
Alikhan R, Cohen AT, Combe S et al. (2003) Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 14(4):341–346
Bahrmann P, Wehling M, Ropers D et al. (2014) Optimale Schlaganfallprävention bei geriatrischen Patienten mit Vorhofflimmern. Konsensbericht eines Interdisziplinären Expertengremiums. MMW Fortschr Med 156 Suppl.3:84–8
Connolly SJ, Camm AJ, Halperin JL et al. (2011) Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365:2268–76
ESC Pocket Guidelines (2013) Leitlinien für das Management von Vorhofflimmern. Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. http://leitlinien.dgk.org/files/Pocket_Leitlinien_Vorhofflimmern_Update2013.pdf, gesehen 21.5.2015
Fuster V, Rydén LE, Cannom DS et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114(7):e257–354
Fuster V, Rydén LE, Cannom DS et al. (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123:e269–367
Hohnloser SH, Crijns HJ, van Eickels M et al. (2009) Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360:668–678
January CT, Wann LS, Alpert JS et al. (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:e1–76
Lip GY, Nieuwlaat R, Pisters R et al. (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the Euro Heart Survey on atrial fibrillation. Chest 137:263–72
Nieuwlaat R, Capucci A, Lip GY et al. (2006) Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 27(24):3018–3026
Rossol-Haseroth K, Vogel CU, Reinecke F et al. (2002) Empfehlungen zur Thromboembolieprophylaxe bei internistischen Patienten im Alter. Internist (Berl) 43(9):1134–1147
Roy D, Talajic M, Nattel S et al. (2008) Atrial fibrillation and congestive heart failure investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358(25):2667–2677
Savelieva I, Camm AJ (2001) Clinical trends in atrial fibrillation at the turn of the millenium. J Intern Med 250(5):369–372
Shariff N, Desai RV, Patel K et al. (2013) Rate-control versus rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation. Am J Med 126:887–93
Spyropoulos AC, Merli G (2006) Management of venous thromboembolism in the elderly. Drugs Aging 23(8):651–671
Wehling M (2011) Wer schützt Ärzte und Patienten vor Leitlinien Dtsch Med Wochenschr 136, 2560–2561
Literatur
Arzneimittelkommission der deutschen Ärzteschaft (2008) Fluoroquinolones: psychiatric adverse effects. Prescrire Int 17(93):20
Board M, Allen SC (2006) A simple drawing test to identify patients who are unlikely to be able to learn to use an inhaler. Int J Clin Pract 60(5):510–513
Buhl R, Berdel D, Criée CP et al. (2006) Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma. Pneumologie 60(3):139–177
Crisafulli E, Morandi A, Olivini A et al. (2014) Rehabilitation and supportive therapy in elderly patients with Chronic Obstructive Pulmonary Disease. Eur J Intern Med 25:329–35
GOLD (Global Initiative for Chronic Obstructive Lung Disease) (2015) Global Strategy for the Diagnosis, Management and Prevention of COPD. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Apr2.pdf. Gesehen 26.05.2015
Jara M, Lanes SF, Wentworth C 3rd et al. (2007) Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf 30(12):1151–1160
Kircher W (2013) Pharmazeutische Anwendungshilfen in der Gerontopharmakologie. Der Internist 2013/1:110–117
Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3(11): e442
Müller D, Szucs TD (2007) Influenza vaccination coverage rates in 5 European countries: a population-based crosssectional analysis of the seasons 02/03, 03/04 and 04/05. Infection 35(5):308–319
Rabe KF, Hurd S, Anzueto A et al. (2007) Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176(6):532–555
Salpeter SR (2007) Bronchodilators in COPD: impact of betaagonists and anticholinergics on severe exacerbations and mortality. Int J Chron Obstruct Pulmon Dis 2(1):11–18
Salpeter SR, Ormiston TM, Salpeter EE. (2004) Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 125:2309–21
Schirnhofer L, Lamprecht B, Vollmer WM et al. (2007) COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) Study. Chest 131(1):29–36
Vogelmeier C, Hederer B, Glaab T et al. (2011) Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364:1093–1103
Weel C van (1996) Chronic diseases in general practice: the longitudinal dimension. Eur J Gen Pract 2:17–21
Wilchesky M, Ernst P, Brophy JM et al. (2012) Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest 142:305–11
Literatur
Bliuc D, Nguyen ND, Nguyen TV et al. (2013) Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men. J Bone Miner Res 28:2317–2324
Chrischilles EA, Butler CD, Davis CS et al. (1991) A model of lifetime osteoporosis impact. Arch Intern Med 151:2026–2032
Dachverband Osteologie (2014) Prophylaxe, Diagnostik und Therapie der OSTEOPOROSE bei Männern ab dem 60. Lebensjahr und bei postmenopausalen Frauen Kurz- und Langfassung: http://www.dv-osteologie.org/uploads/Leitlinie%202014/DVO-Leitlinie%20Osteoporose%202014%20Kurzfassung%20und%20Langfassung%2018.%2009.%202014.pdf. Gesehen: 26.05.2015
Duque G, Mallet L, Roberts A et al. (2007) To treat or not to treat, that is the question: proceedings of the Quebec symposium for the treatment of osteoporosis in long-term care institutions,.Saint-Hyacinthe, Quebec, November 5th, 2004. J Am Med Dir Assoc 8(3 Suppl 2): e67–73
Looker AC, Orwoll ES, Johnston CC Jr et al. (1997) Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 12:1761–1768
Lyles KW, Colón-Emeric CS, Magaziner JS et al. (2007) HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809
Literatur
Abram K, Pedersen-Bjergaard U, Borch-Johnsen K et al. (2006) Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: a literature survey. J Diabetes Complications 20:402–408
ACCORD (The Action to Control Cardiovascular Risk in Diabetes Study Group) (2008) Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358:2545–2559
ADVANCE (The ADVANCE Collaborative Group) (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
Allen KV, Frier BM, Strachan MWJ (2004) The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 490:169–175
American Diabetes Association (2009) Standards of medical care in diabetes. Diabetes Care, 32:S13–S61
Braun A, Muller UA, Leppert K et al. (2004) Structured treatment and teaching of patients with type 2 diabetes mellitus and impaired cognitive function – the DICOF trial. Diabet Med 21:999–1006
Burkhardt H, Karaminejad E, Gladisch R (2006) A short performance-test can help to predict adherence to self-administration of insulin in elderly patients with diabetes. Age Ageing 35:449–452
Cryer PE, Davis SN, Shamon H (2003) Hypoglycemia in Diabetes. Diabetes Care 26:1902–1912
Dargie HJ, Hildebrandt PR, Riegger GA et al. (2007) A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 49(16):1696–1704
DCCT (The Diabetes Control And Complications Trial Research Group) (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
DDG (Deutsche Diabetesgesellschaft) (2004)Diabetes im Alter. http://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/EBL_Alter_2004.pdf. Gesehen 1.2.2016
Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705
Duckworth W, Abraira C, Moritz T et al. (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360(2):129–139
Erdmann E, Charbonnel B, Wilcox RG et al. (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease. Diabetes Care 30:2773–2778
Gaede P, Vedel P, Larsen N et al. (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393
Hader C, Beischer W., Braun A. et al. (2005) Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. Diabet Stoffw 13:31–56
Hauner H (2006) Die Kosten des Diabetes und seiner Komplikationen in Deutschland. Dtsch Med Wochenschr 131:S240–242
Holstein A, Plaschke A, Egberts EH (2001) Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 17:467–473
Josephkutty S, Potter JM (1990) Comparison of tolbutamide and metformin in elderly diabetic patients. Diabet Med 7:510–514
Lipscombe LL, Gomes T, Lèvesque LE et al. DA (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298:2634–2653
Meier C, Kraenzlin ME, Bodmer M et al. (2008) Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820–825
Meneilly GS (1999) Pathophysiology of type 2 diabetes in the elderly. Clin Geriatr Med 15:239–253
Mooradian AD, Albert SG, Wittry S et al. (2000) Dose response profile of acrabose in older subjects with type 2 diabetes. Am J Med Sci 319:334–337
Moty C, Barberger-Gateau P, De Sarasqueta AM et al. (2003) Risk adjustment of quality indicators in French long term care facilities for elderly people. A preliminary study. Rev Epidemiol Sante Publique 51:327–338
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1–S246. http://www.kidney.org/professionals/KDOQI. Gesehen 15.1.2009
Phillips P, Phil D, Rolls B et al. (1984) Reduced thirst after water dehydration in healthy elderly men. N Engl J Med 311:753–759
Pickering G (2004) Frail elderly, nutritional status and drugs. Arch Gerontol Geriatr 38:174–180
Schwarz SL, Gerich JE, Marcellari A et al. (2008) Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment–naive elderly patients with type 2 diabetes. Diab Obes Metab 10:652–660
Shepherd J, Blauw GJ, Murphy MB et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623–1630
Shorr RI, Ray WA, Daugherty JR et al. (1997) Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 157:1681–1686
Staa T van, Abenhaim L, Monette J (1997) Rates of hypoglycaemia in users of sulfonylureas. J Clin Epidemiol 50(6):735–741
Skyler JS, Bergenstal R, Bonow RO et al. (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 20;53(3):298–304
The Diabetes Prevention Program Research Group (Prepared by Jill Crandall, David Schade, Yong Ma et al.) (2006) The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol Med Sci 2006, 61A: 1075–1081
Thomson FJ, Masson EA, Leeming JT et al. (1991) Lack of knowledge of symproms of hypoglycaemia by elderly diabetic patients. Age Ageing 20:404–406
Thorslund S, Toss G, Nilsson I et al. (1990) Prevalence of protein-energy malnutrition in a large population of elderly people at home. Scand J Prim Health Care 8:243–248
Turnbull PJ, Sinclair AJ (2002) Evaluation of nutritional status and its relationship with functional status in older citizens with diabetes mellitus using the Mini Nutritional Assessment (MNA) tool. A preliminary investigation. J Nutr Health Aging 6:116–120
UKPDS (UK Prospective Diabetes Study (UKPDS) Group) (1998) Effect of intensive blood–glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 352:854–865
Van Den Berghe G, Wouters P, Weekers F et al. (2001) Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359–1367
Wehling M (2008) Arzneimitteltherapie im Alter: Zu viel und zu wenig, was tun? Ein neues Bewertungssystem: fit for the aged (FORTA). Dtsch Med Wochenschr 133:2289–2291
Yki-Järvinen H, Kauppila M, Kujansuu E et al. (1992) Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327:1426–1433
Zeyfang A, Feucht I, Fetzer G et al. (2001) Eine strukturierte geriatrische Diabetiker-Schulung (SGS) ist sinnvoll. Diabet Stoffw 10:203–207
Literatur
Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh–Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387–392
Aarsland D, Ballard C, Walker Z et al. (2009) Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8:613–618
Andersen-Ranberg K, Vasegaard L, Jeune B (2001) Dementia is not inevitable: a population-based study of Danish centenarians. J Gerontol B Psychol Sci Soc Sci 56:152–159
Atri A, Shaughnessy LW, Locascio JJ, Growdon JH (2008) Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22:209–221
Ballard C, Hanney ML, Theodoulou M et al. (2009) The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 8:151–157
Banerjee S, Hellier J, Dewey M et al. (2011) Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378:403–411
Bang J, Spina S, Miller BL (2015) Frontotemporal dementia. Lancet 2015;386:1672–1682
Berman K, Brodaty H, Withall A et al. (2012) Pharmacologic treatment of apathy in dementia. Am J Geriatr Psychiatry 20:104–122
Boyle PA, Malloy PF (2004) Treating apathy in Alzheimer‘s disease. Dement Geriatr Cogn Disord 17:91–99
Coupland C, Dhiman P, Morriss R et al. (2011) Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 343:d4551
Craig D, Birks J (2005) Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev CD004744
Craig D, Birks J (2006) Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev CD004746
Cummings J, Isaacson S, Willimas H et al. (2013) Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383:533–540
Cummings JL, Lyketsos CG, Peskind ER et al (2015) Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA 314:1242–1254
DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde), DGN (Deutsche Gesellschaft für Neurologie) (2015) Revidierte S3-Leitlinie Demenzen. https://www.dgppn.de/publikationen/s3-leitlinie-demenzen.html. Gesehen 05.11.2015
Dodel R, Belger M, Reed C et al. (2015) Determinants of societal costs in Alzheimer's disease: GERAS study baseline results. Alzheimers Dement 11:933–945
Emre M, Aarsland D, Albanese A et al. (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351:2509–2518
Emre M, Tsolaki M, Bonuccelli U et al. (2010) Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:969–977
Enache D, Winblad B, Aarsland D (2011) Depression in dementia: epidemiology, mechanisms and treatment. Curr Opin Psychiatry 24:461–472
Erkinjuntti T, Gauthier S (2009) The concept of vascular cognitive impairment. Front Neurol Neurosci. 24:79–85
European Medicines Agency (2009) Committee for medicinal products for human use. Guidelines on medicinal products for the treatment of Alzheimer‘s disease and other dementias. http://www.ema.europa.eu/pdfs/human/ewp/055395en.pdf. Available 11.01.2010
Fuchs GA, Gemende I, Herting B et al. (2004) Dementia in idiopathic Parkinson’s syndrome. J Neurol 251 (Suppl 6): VI/28–32
Greig SL. Memantine ER/Donepezil: A Review in Alzheimer’s Disease. CNS Drugs 2015 Oct 30 [Epub ahead of print]
Hansen RA, Gartlehner G, Webb AP et al. (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer‘s disease: a systematic review and meta–analysis. Clin Interv Aging 3:211–225
Herrmann N, Lanctot KL (2005) Do atypical antipsychotics cause stroke? CNS Drugs 19:91–103
Herrmann N, Black SE, Chow T et al. (2012) Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry 20:789–797
Hogan DB (2006) Donepezil for severe Alzheimer‘s disease. Lancet 367:1031–1032
Hogan DB, Patterson C (2002) Progress in clinical neurosciences: Treatment of Alzheimer‘s disease and other dementias – review and comparison of the cholinesterase inhibitors. Can J Neurol Sci 29:306–314
Howard R, McShane R, Lindesay J et al. (2012) Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med 366:893–903
Husebo BS, Ballard C, Sandvik R et al. (2011) Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ 343:d4065
Ibach B, Lange K, Haen E (2003) Das cholinerge System und die Therapie der Alzheimer-Demenz. In: Förstl H (Hrsg) Antidementiva. Urban & Fischer, München, S 93–143
IQWIG (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen)(2011) Responderanalysen zu Memantin bei Alzheimer Demenz www.iqwig.de/download/A10-06_Rapid-Report_Responderanalysen_zu_Memantin_bei_Alzheimer_Demenz.pdf. Gesehen 01.10.2012
Johansson C, Ballard C, Hansson O et al. (2011) Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. Int J Geriatr Psychiatry 26:206–213
Kales HC, Kim HM, Zivin K (2012) Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 169:71–79
Kavirajan H, Schneider LS (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 6:782–792
Lobo A, Launer LJ, Fratiglioni L et al. (2000) Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54:S4–9
Lopez OL, Becker JT, Wahed AS et al. (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80:600–607
Maidment I, Fox C, Boustani M (2006) Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst Rev, CD004747
McKeith IG, Dickson DW, Lowe J et al. (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872
Ngandu T, Lehtisalo J, Solomon A et al (2015) A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385:2255–2263
Mitchell SL (2015) Clinical Practice. Advanced Dementia. NEJM 3712:2533–2540
Neary D, Snowden J, Mann D (2005) Frontotemporal dementia. Lancet Neurol 2005;4:771–780
Nelson JC, Devanand DP (2011) A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc 59:577–585
O‘Brien JT, Thomas A (2015) Vascular Dementia. Lancet 386:1698–1706
OECD Organisation for Economic Co-operation and Development (2015) Health at a Glance 2015. OECD Publishing
Ott A, Breteler MM, Harskamp F van, Stijnen T, Hofman A (1998) Incidence and risk of dementia. The Rotterdam Study. Am J Epidemiol 147:574–580
Porsteinsson AP, Drye LT, Pollock BG et al. (2014) Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 311:682–691
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 9:63–75
Román GC, Salloway S, Black SE et al. (2010) Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke 41:1213–1321
Samuel W, Caligiuri M, Galasko D et al. (2000) Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 15:794–802
Schneider LS, Dagerman K, Insel PS (2006) Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14:191–210
Schneider LS, Dagerman KS, Higgins JP et al. (2011) Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 68:991–998
Snitz BE, O‘Meara ES, Carlson MC et al. (2009) Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 302:2663–2670
Srinivasan V, Brzezinski A, Pandi-Perumal SR et al. (2011) Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? Prog Neuropsychopharmacol Biol Psychiatry 35:913–923
Statistisches Bundesamt (2009) Bevölkerung Deutschlands bis 2060 – Ergebnisse der 12. koordinierten Bevölkerungsvorausberechnung, www.destatis.de. Gesehen 11.01.2010
Sterke CS, Ziere G, van Beeck EF et al. (2012) Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in nursing home residents with dementia. Br J Clin Pharmacol 73:812–820
Tan MS, Yu JT, Tan CC et al. (2015) Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis 43:589–60
Tariot PN, Schneider LS, Cummings J et al. (2011) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 68:853–861
Trifirò G, Gambassi G, Sen EF et al. (2010) Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med 152:418–425
Vellas B, Coley N, Ousset PJ et al. (2012) Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 11:851–859
Walker Z, Possin KL, Boeve BF, Aarsland D (2015) Lewy body dementias. Lancet 2015;386:1683–1697
Winblad B, Kilander L, Eriksson S et al. (2006) Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 367:1057–1065
Literatur
Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 20(10):1255–1263
Bennett DA, Beckett LA, Murray AM et al. (1996) Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334(2):71–76
Brooks DJ (2004) Safety and tolerability of COMT inhibitors. Neurology 62(Suppl 1):S39–46
Buhmann C (2008) Diagnostik und Therapie des Morbus Parkinson beim älteren Patienten. NeuroGeriatrie 5:137–145
Chou KL, Messing S, Oakes D et al. (2005) Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 28(5):215–219
Csoti I, Fornadi F (2008) Medikamentöse Interaktionen in der Parkinson-Therapie. NeuroGeriatrie 5:160–168
Dell‘Agnello G, Ceravolo R, Nuti A et al. (2001) SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol 24(4):221–227
Deutsche Gesellschaft für Neurologie (2009) Leitlinien der Deutschen Gesellschaft für Neurologie 2008. Parkinson-Syndrome. Diagnostik und Therapie. http://www.dgn.org. Gesehen 18.12.2009
Ebersbach G (2008) Depressive Störungen bei der Parkinson-Erkrankung. NeuroGeriatrie 5:146–153
Emre M, Aarsland D, Albanese A et al. (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351(24):2509–2518
Emre M, Poewe W, De Deyn PP et al. (2014) Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol. Jan-Feb;37(1):9–16.
Fahn S, Oakes D, Shoulson I et al. (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351(24):2498–2508
Goetz CG, Blasucci LM, Leurgans S et al. (2000) Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55(6):789–794
Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry 70(6):734–738
Janno S, Holi M, Tuisku K et al. (2004) Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia in patients. Am J Psychiatry 161(1):160–163
Jenner P (2005) A novel dopamine agonist for the transdermal treatment of Parkinson’s disease. Neurology 65(2 Suppl 1):S3–5
Mitchell SL, Sullivan EA, Lipsitz LA (1997) Exclusion of elderly subjects from clinical trials for Parkinson disease. Arch Neurol 54(11):1393–1398
Nutt JG (2003) Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson’s disease. Exp Neurol 184(1):9–13
Parkinson Study Group (2000) A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 23(1):34–44
Poewe WH, Wenning GK (1998) The natural history of Parkinson’s disease. Ann Neurol 44(3 Suppl 1):S1–9
Pollak P, Tison F, Rascol O et al. (2004) Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75(5):689–695
Rajput AH, Offord KP, Beard CM et al. (1984) Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 16(3):278–282
Rascol O, Brooks DJ, Melamed E et al. (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463): 947–954
Reddy S, Factor SA, Molho ES et al. (2002) The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 17(4):676–681
Rijk MC de, Launer LJ, Berger K (2000) Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(11 Suppl 5):S21–23
Santamaría J, Tolosa E, Valles A (1986) Parkinson’s disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 36(8):1130–1133
Schwarz J, Storch A (2007) Parkinson-Syndrome. Kohlhammer, Stuttgart
Starkstein SE, Preziosi TJ, Bolduc PL et al. (1990) Depression in Parkinson‘s disease. J Nerv Ment Dis 178(1):27–31
Stephen PJ, Williamson J (1984) Drug-induced parkinsonism in the elderly. Lancet 2(8411):1082–1083
Szegedi A, Jansen WT, Willigenburg AP van et al. (2009) Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 70:344–353
The Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328(3):176–183
Verhagen Metman L, Del Dotto P, van den Munckhof P et al. (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 50(5):1323–1326
Literatur
Alexopoulos GS (2005) Depression in the elderly. Lancet 365:1961–1970
Alexopoulos GS, Katz IR, Reynolds CF 3rd et al. (2001) The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad Med Spec No Pharmacotherapy:1–86
Alexopoulos GS, Borson S, Cuthbert BN et al. (2002) Assessment of late life depression. Biol Psychiatry 52:164–174
Bauer M, Bschor T, Pfennig A et al. (2007) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8:67–104
Bondareff W, Alpert M, Friedhoff AJ et al. (2000) Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 157:729–736
Cipriani A, Furukawa TA, Salanti G et al. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758
Coupland C, Dhiman P, Morriss R et al. (2011) Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 343:d4551
DGPPN, BÄK, KBV et al. (Hrsg) (2015) S3-Leitlinie und Nationale VersorgungsLeitlinie (NVL) Unipolare Depression. 2. Auflage. abrufbar unter http://www.leitlinien.de/nvl/depression/ Gesehen 26.11.2015
DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde) (2012) Stellungnahme zur QTc-Zeit-Verlängerung unter Citalopram und Escitalopram. http://www.dgppn.de/publikationen/stellungnahmen/detailansicht/browse/1/article/141/zur-qtc-zeit.html. Gesehen 01.10.2012
Eyding D, Lelgemann M, Grouven U et al. (2010) Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 341:c4737
Gebara MA, Lipsey KL, Karp JF, Nash MC, Iaboni A, Lenze EJ (2015) Cause or Effect? Selective Serotonin Reuptake Inhibitors and Falls in Older Adults: A Systematic Review. Am J Geriatr Psychiatry. 23:1016–1028
Hackett ML, Pickles K (2014) Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke 9: 1017–1025
Hawton K, Heeringen K van (2009) Suicide. Lancet 373:1372–1381
Hausner L, Damian M, Sartorius A, Froelich L (2011) Efficacy and cognitive side effects of electroconvulsive therapy (ECT) in depressed elderly inpatients with coexisting mild cognitive impairment or dementia. J Clin Psychiatry 72:91–97
Hegeman JM, Kok RM, van der Mast RC et al. (2012) Phenomenology of depression in older compared with younger adults: meta-analysis. Brit J Psychiatry 200:275–281
Heok KE, Ho R (2008) The many faces of geriatric depression. Curr Opin Psychiatry 21:540–545
Iovieno N, Tedeschini E, Ameral VE, Rigatelli M, Papakostas GI (2011) Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials. Int Clin Psychopharmacol 26: 69–74
Koethe D, Mattern M, Herpertz S (2014) Psychotherapeutische Arbeit mit älteren Patienten. Nervenarzt 85:1345–1351
Kok RM,Nolen WA, Heeren TJ (2012) Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J Affect Disord 141: 103–115.
McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR (2012) Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379: 721–728
Pinquart M, Duberstein PR, Lyness JM (2006) Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry 163:1493–1501
Pinquart M, Duberstein PR, Lyness JM (2007) Effects of psychotherapy and other behavioral interventions on clinically depressed older adults: a meta-analysis. Aging Ment Health 11:645–657
Raskin J, Wiltse CG, Siegal A et al. (2007) Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 164:900–909
Rodda J, Walker Z, Carter J (2011) Depression in older adults. BMJ 343:d5219
Samad Z, Brealey S, Gilbody S (2011) The effectiveness of behavioural therapy for the treatment of depression in older adults: a meta-analysis. Int J Geriatr Psychiatry 26:1211–1220
Sterke CS, Ziere G, van Beeck EF et al. (2012) Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in nursing home residents with dementia. Br J Clin Pharmacol 73:812–820
Taylor W (2014) Depression in the Elderly. NEJM 371:1228–1236
Tedeschini E, Levkovitz Y, Iovieno N et al. (2011) Efficacy of antidepressants for late-life depression: A meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatr 72:1660–1668
Tess AV, Smetana GW (2009) Medical evaluation of patients undergoing electroconvulsive therapy. N Engl J Med 360:1437–1444
Literatur
Ancoli-Israel S, Cooke JR (2005) Prevalence and comorbidity of insomnia and effect on functioning in elderly populations. J Am Geriatr Soc 53:S264–271
Bennett T, Bray D, Neville MW (2014) Suvorexant, a Dual Orexin Receptor Antagonist for the Management of Insomnia. PT. 39: 264–266
Bloom HG, Ahmed I, Alessi CA et al. (2009) Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc 57:761–789
Culberson JW, Ziska M (2008) Prescription drug misuse/abuse in the elderly. Geriatrics 63:22–31
Dolder C, Nelson M, McKinsey J (2007) Use of non-benzodiazepine hypnotics in the elderly: are all agents the same? CNS Drugs 21:389–405
Dundar Y, Dodd S, Strobl J et al. (2004) Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol 19:305–322
Erman MK (2005) Therapeutic options in the treatment of insomnia. J Clin Psychiatry 66 (Suppl 9):18–23
Flaherty JH (2008) Insomnia among hospitalized older persons. Clin Geriatr Med 24:51–67
Foley DJ, Monjan A, Simonsick EM et al. (1999) Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. Sleep 22 (Suppl 2):S366–372
Glass J, Lanctot KL, Herrmann N et al. (2005) Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 331:1169
Kupfer DJ, Reynolds CF 3rd (1997) Management of insomnia. N Engl J Med 336:341–346
Melton ST, Wood JM, Kirkwood CK (2005) Eszopiclone for insomnia. Ann Pharmacother 39:1659–1666
Svarstad BL, Mount JK (2001) Chronic benzodiazepine use in nursing homes: effects of federal guidelines, resident mix, and nurse staffing. J Am Geriatr Soc 49:1673–1678
Vaz Fragoso CA, Gill TM (2007) Sleep complaints in community-living older persons: a multifactorial geriatric syndrome. J Am Geriatr Soc 55:1853–1866
Winkelmann JW (2015) Insomnia Disorder. NEJM 373:1437–1444
Wolkove N, Elkholy O, Baltzan M et al. (2007) Sleep and aging: 1. Sleep disorders commonly found in older people. CMAJ 176:1299–1304
Literatur
Caputo F, Vignoli T, Leggio L, Addolorato G, Zoli G, Bernardi M (2012) Alcohol use disorders in the elderly. A brief overview from epidemiology to treatment options. Exp Gerontol 47:411–416
Culberson JW, Ziska M (2008) Prescription drug misuse / abuse in the elderly. Geriatrics 63:22–31
AWMF online (Hrsg.) (2015) S3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener Störungen. Abrufbar unter http://www.dg-sucht.de/s3-leitlinien/ http://www.dg-sucht.de/fileadmin/user_upload/pdf/leitlilnien/22_4_2015_AWMF_76-001_S3_Leitlinie_Alkoholbez_St%C3%B6rungen.pdf. Gesehen am 1.2.2016
Dowling GJ, Weiss SR, Condon TP (2008) Drugs of abuse and the aging brain. Neuropharmacology 33:209–218
Gossop M, Moos R (2008) Substance misuse among older adults: A neglected but treatable problem. Addiction 103:347–348
Gfroerer J, Penne M, Pemberton M, Folsom R (2003) Substance abuse treatment need among older adults in 2020: The impact of the aging baby-boom cohort. Drug and Alcohol Dependence 69:127–135
Hoffmann F, Glaeske G (2014) Benzodiazepinhypnotika, Zolpidem und Zopiclon auf Privatrezept. Nervenarzt 85:1402–1409
Janhsen K, Roser P, Koffmann K (2015) The problems of long-term treatment with benzodiazepines and related substances. Dtsch Ärztebl Int 112:1–7
Johnell K, Fastbom J (2011) Gender and use of hypnotics or sedatives in old age: a nationwide register-based study. Int J Clin Pharm 33:788–793
Koechl B, Unger A, Fischer G (2012) Age-related aspects of addiction. Gerontology 58:540–544
Maschke M et al. (2014) Leitlinien für Diagnostik und Therapie in der Neurologie. Alkoholdelir und Verwirrtheitszustände. Abrufbar unter http://www.dgn.org/images/red_leitlinien/LL_2014/PDFs_Download/030006_LL_Alkoholdelir_und_Verwirrtheitszust%C3%A4nde_final.pdf
Wolter DK. Alkohol im Alter (2015) Trinkgewohnheiten, risikoarmer Konsum und alkoholbezogene Störungen. Z Gerontol Geriatr 48:557–570
Wu L-T, Blazer DG (2011) Illicit and nonmedical drug use among older adults: A review. J Aging Health 23:481–504
Literatur
Ammon HPT (Hrsg) (2001) Arzneimittelneben- und wechselwirkungen. Wissenschaftliche Verlagsgesellschaft, Stuttgart
Andrade SE, Martinez C, Walker AM (1998) Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol 51(12):1357–1365
Arzneimittelkommission der deutschen Ärzteschaft (2004) Arzneimittelbrief 2003, 37, 6b., Deutsches Ärzteblatt 101:A3365
Attal N, Cruccu G, Haanpää M et al. (2006) EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13(11):1153–1169
Baxter H (Ed) (2008) Stockley´s drug interactions 2008. Pharmaceutical Press, London
Bombardier C, Laine L, Reicin A et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343(21):1520–1528
Bradley JD, Brandt KD, Katz BP et al. (1991) Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 325(2):87–91
Brattberg G, Parker MG, Thorslund M (1996) The prevalence of pain among the oldest old in Sweden. Pain 67(1):29–34
Brodie MJ, Overstall PW, Giorgi L (1999) Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 7(1):81–87
Brown MB, Martin GP, Jones SA et al. (2006) Dermal and transdermal drug delivery systems: current and future prospects. Drug delivery 13 (3):175–187
Bruckenthal P (2008) Assessment of pain in the elderly adult. Clin Geriatr Med 24(2):213–236
Chan FK, Hung LC, Suen BY et al. (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347(26):2104–2110
Charette SL, Ferrell BA (2007) Rheumatic diseases in the elderly: assessing chronic pain. Rheum Dis Clin North Am 33(1):109–122
Cohen HW, Gibson G, Alderman MH (2000) Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 108(1):2–8
Cruccu G, Anand P, Attal N et al. (2004) EFNS guidelines on neuropathic pain assessment. Eur J Neurol 11(3):153–162
Dworkin RH, Backonja M, Rowbotham MC et al. (2003) Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 60(11):1524–1534
Ferrell BA, Ferrell BR, Osterweil D (1990) Pain in the nursing home. J Am Geriatr Soc 38(4):409–414
Finnerup NB, Otto M, McQuay HJ et al. (2005) Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118(3):289–305
Frondini C, Lanfranchi G, Minardi M et al. (2007) Affective, behavior and cognitive disorders in the elderly with chronic musculoskelatal pain: the impact on an aging population. Arch Gerontol Geriatr 44 (Suppl 1):167–171
Gaudreau JD, Gagnon P, Roy MA et al. (2007) Opioid medications and longitudinal risk of delirium in hospitalized cancer patients. Cancer 109(11):2365–2373
Giron MS, Fastbom J, Winblad B (2005) Clinical trials of potential antidepressants: to what extent are the elderly represented: a review. Int J Geriatr Psychiatry 20(3):201–217
Gupta SK, Hwang S, Southam M et al. (2005) Effects of application site and subject demographics on the pharmacokinetics of fentanyl HCl patient-controlled transdermal system (PCTS). Clinical pharmacokinetics. 44 Suppl 1:25–32
Haslam C, Nurmikko T (2008) Pharmacological treatment of neuropathic pain in older persons. Clin Interv Aging (1):111–120
Hedenmalm K, Spigset O (2002) Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol 58:265–274
Henry D, Lim LL, Garcia Rodriguez LA et al. (1996) Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 312(7046):1563–1566
Hippisley-Cox J, Coupland C, Logan R (2005) Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 331(7528):1310–1316
Jüni P, Rutjes AW, Dieppe PA (2202) Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 324(7349):1287–1288
Kaestli LZ, Wasilewski-Rasca AF, Bonnabry P et al. (2008) Use of transdermal drug formulations in the elderly. Drugs & aging 25(4):269–280
Kean WF, Rainsford KD, Kean IR (2008) Management of chronic musculoskeletal pain in the elderly: opinions on oral medication use. Inflammopharmacology 6(2):53–75
Lancet (2013) Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individualparticipant data from randomised trials. 382:769–779
Lapane KL, Spooner JJ, Mucha L et al. (2001) Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care. J Am Geriatr Soc 49(5):577–584
Larsen RH, Nielsen F, Sorensen JA et al. (2003) Dermal penetration of fentanyl: inter- and intraindividual variations. Pharmacology & toxicology 93(5):244–248
Laurell H, Hansson LE, Gunnarsson U (2006) Acute abdominal pain among elderly patients. Gerontology 52:339–344
Leppik IE, Epilepsy Foundation of America (2005) Choosing an antiepileptic. Selecting drugs for older patients with epilepsy. Geriatrics 60(11):42–47
Mattenklodt P, Ingenhorst A, Wille C et al. (2008) Multimodale Gruppentherapie bei Senioren mit chronischen Schmerzen. Schmerz 22:551–5561
McCleane G (2008) Pain perception in the elderly patient. Clin Geriatr Med 24(2):203–211
McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296(13):1633–1644
McQuay HJ (1997) Opioid use in chronic pain. Acta Anaesthesiol Scand 41(1 Pt 2):175–183
Mercadante S, Arcuri E (2007) Pharmacological management of cancer pain in the elderly. Drugs Aging 24(9):761–776
Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286(8):954–959
Namaka M, Gramlich CR, Ruhlen D et al. (2004) A treatment algorithm for neuropathic pain. Clin Ther. 2004 Jul;26(7):951–79. Review. Erratum in: Clin Ther. 2004 Dec;26(12):2163
Nikolaus T, Zeyfang A (2004) Pharmacological treatment for persisitent non-malignant pain in older persons. Drugs Aging 21:19–41
Pergolizzi J, Böger RH, Budd K et al. (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8(4):287–313
Ruoff GE (2002) Challenges of managing chronic pain in the elderly. Semin Arthritis Rheum 32(3 Suppl 1):43–50
Sauaia A, Min SJ, Leber C et al. (2005) Postoperative pain management in elderly patients: correlation between adherence to treatment guidelines and patient satisfaction. J Am Geriatr Soc 53(2):274–282
Schmedtje JF Jr, Ji YS, Liu WL et al. (1997) Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 272(1):601–608
Schuler MS, Basler HD, Hesselbarth S et al. (2004) Einfluss von Schmerzwahrnehmung, Morbidität und aktueller Stimmung auf funktionelle Beeinträchtigung Älterer mit chronischen Schmerzen. Z Gerontol Geriatr 37(4):257–264
Semla TP, Beizer JL, Higbee MD (2003) Geriatric dosage handbook. 9th edn, Lexi Comp, Hudson
Tasmuth T, Härtel B, Kalso E (2002) Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 6(1):17–24
Vadalouca A, Siafaka I, Argyra E et al. (2006) Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. Ann N Y Acad Sci 1088:164–186
Van den Bemt PM, Geven LM, Kuitert NA et al. (2002) The potential interaction between oral anticoagulants and acetaminophen in everyday practice. Pharm World Sci 24(5):201–204
Waldvogel HH (1996) Analgetika, Antinozizeptiva, Adjuvantien. Handbuch für die Schmerzpraxis. Springer, Berlin Heidelberg New York Tokyo
Wehling, M (2008) Arzneimitteltherapie im Alter: Zu viel und zu wenig, was tun? Dtsch Med Wochenschr 133, 2289–2291
WHO (World Health Organisation) (2007) Normative Guidelines on pain management. Geneva WHO. www.who.int/medicines/areas/quality_safety/Tagelphi_study_pain_guidelines.pdf. Gesehen 27.12.2009
WHO (World Health Organisation (1996) Cancer pain relief with a guide to opioid availability. 2nd edn, WHO, Geneva
Won AB, Lapane KL, Vallow S et al. (2004) Persistent nonmalignant pain and analgesic prescribing patterns in elderly nursing home residents. J Am Geriatr Soc 52(6):867–874
Yost JH, Morgan CJ (1994) Cardiovascular effects of NSAISDs. J Musculoskel Med 11:22–34
Zwakhalen SM, Hamers JP, Abu-Saad HH et al. (2006) Pain in elderly people with severe dementia: a systematic review of behavioural pain assessment tools. BMC Geriatr 6:3
Literatur
Aapro MS, Cameron DA, Pettengell R et al. (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42(15):2433–2453
Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13(Suppl 3):33–36
Albert US (Hrsg.) (2008) Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Zuckschwerdt, München
Amado RG, Wolf M, Peeters M et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626–1634
André T, Boni C, Mounedji-Boudiaf L et al. (2004) Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351
Ayanian JZ, Zaslavsky AM, Fuchs CS et al. (2003) Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 21(7):1293–1300
Begg CB, Carbone PP (1983) Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 52(11):1986–1992
Bliss JM, Kilburn LS, Coleman RE et al. (2012) Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol. 30(7):709–17
Bergh J, Holmquist M (2001) Who should not receive adjuvant chemotherapy? International databases. J Natl Cancer Inst Monogr 30:103–108
Bokemeyer C, Aapro MS, Courdi A et al. (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43(2):258–270
Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304(1):10–15
Bonneterre J, Thürlimann B, Robertson JF et al. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18(22):3748–3757
Borkowski JM, Duerr M, Donehower RC et al. (1994) Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 33(6):493–496
Bouchardy C, Rapiti E, Blagojevic S et al. (2007) Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 25(14):1858–1869
Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A(7):1135–1141
Cameron D, Casey M, Press M et al. (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112(3):533–543
Chapman JA, Meng D, Shepherd L et al. (2008) Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 100(4):252–260
Christman K, Muss HB, Case LD et al. (1992) Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience (see comment). JAMA 268(1):57–62
Coates AS, Keshaviah A, Thürlimann B et al. (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (5): 486–492Tumorerkrankungen
Cohendy R, Rubenstein LZ, Eledjam JJ (2001) The mini nutritional assessment-short form for preoperative nutritional evaluation of elderly patients. Aging (Milano 13(4):293–297
Crivellari D, Bonetti M, Castiglione-Gertsch M et al. (2000) Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 18(7):1412–1422
Cronin DP, Harlan LC, Potosky AL et al. (2006) Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol 101(10):2308–2318
Cunningham D, Allum WH, Stenning SP et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20
Cutsem E van, Rivera F, Berry S et al. (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20(11):1842–1847
De Boer MF, Ryckman RM, Pruyn JF et al. (1999) Psychosocial correlates of cancer relapse and survival: A literature review. Patient Edu Counsel (37):215–230
Des Guetz G, Uzzan B, Nicolas P et al (2012) Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis. Crit Rev Oncol Hematol. 84 (3): 340–9
Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J et al. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100.000 women in 123 randomised trials. Lancet. 379(9814):432–44
EBCTCG (Early Breast Cancer Trialists‘ Collaborative Group) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717
Edwards BK, Brown ML, Wingo PA et al. (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97(19):1407–1427
Edwards BK, Howe HL, Ries LA et al. (2002) Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94(10):2766–2792
Eichhorst BF, Busch R, Stilgenbauer S et al. (2009) First line therapy with fludarabine compared to chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114:3382–3391
Elkin EB, Hurria A, Mitra N et al. (2006) Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 24(18):2757–2764
Endres HG, Wedding U, Pittrow D et al. (2009) Prevalence of anemia in elderly patients in primary care: impact on 5-year mortality risk and differences between men and women. Curr Med Res Opin 25(5):1143–1158
Estey, E (2007) Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 25 (14):1908–1915 Tumorerkrankungen
Ewer MS, O’Shaughnessy JA (2007) Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer 7(8):600–607
Extermann M, Overcash J, Lyman GH et al. (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16 (4): 1582–1587 Tumorerkrankungen
Facon T, Mary JY, Hulin C et al. (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): arandomised trial. Lancet 370(9594):1209–1218
Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223–232
Fernaux P, Mufti GJ, Hellström-Lindberg E et al. (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 28(4):562–9
Folstein MF, Folstein SE, McHugh PR (1975) „Mini-mental state“. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198
Forbes JF, Cuzick J, Buzdar A et al. (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol (1):45–53
Fossati R, Confalonieri C, Torri V et al. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16(10):3439–3460
Freyer G, Geay JF, Touzet S et al. (2005) Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 16(11):1795–1800
Früh M, Rolland E, Pignon JP et al. (2008) Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 26(21):3573–3581
Gelman RS, Taylor SGT (1984) Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 2(12):1404–1413
Geyer CE, Forster J, Lindquist D et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743
Giordano SH, Duan Z, Kuo YF et al. (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24(18):2750–2756
Giovanazzi-Bannon S, Rademaker A, Lai G et al. (1994) Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol 12 (11): 2447–2452 Tumorerkrankungen
Goldhirsch A, Gelman RS, Gelber RD et al. M (1990) Treatment of breast cancer in elderly patients. Lancet 336(8714):564
Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, 10th St. Gallen conference (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18(7):1133–1144
Goldhirsch A, Wood WC, Coates AS et al. (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. (8):1736–47
Hallek M, Fischer K, Fingerle-Rowson G et al.; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164–74
Haller DG, Catalano PJ, Macdonald JS et al. (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23(34):8671–8678
Harter P, du Bois A, Schade-Brittinger C et al. (2005) Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol 16(11):1801–1805
Höffken K, Kolb G, Wedding U (2002) Geriatrische Onkologie. Springer, Berlin Heidelberg New York
Hulin C, Facon T, Rodon P et al. (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 27(22):3664–3670
Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342
Hutchins LF, Unger JM, Crowley JJ et al. (1999) Underrepresentation of patients 65 years of age or older in cancer- treatment trials. N Engl J Med 341(27):2061–2067
Jakesz R, Greil R, Gnant M et al., Austrian Breast and Colorectal Cancer Study Group (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 99(24):1845–53
Jin H, Tu D, Zhao N et al. (2012) Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol. 30(7):718–21
Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354(8):809–820
Jonat W, Gnant M, Boccardo F et al. (2006) Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. (12): 991–6 Tumorerkrankungen
Kabbinavar FF, Schulz J, McCleod M (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23(16):3697–3705
Kabbinavar FF, Hurwitz HI, Yi J et al. (2009) Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 27(2):199–205
Kalbe E, Kessler J, Calabrese P, Smith R, Passmore AP, Brand M, Bullock R (2004) DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry 19(2):136–143
Karnofsky DA, Adelmann WH, Craver FL (1948) The use of nitrogen mustard in the palliative treatment of carcinoma. Cancer 1: 634–656 Tumorerkrankungen
Kantarjian HM, Thomas XG, Dmoszynska A et al. (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 30(21):2670–7
Keating NL, Landrum MB, Klabunde CN et al. (2008) Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 26(15):2532–2537
Kemeny MM, Peterson BL, Kornblith AB et al. (2003) Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21(12):2268–2275
Knauf WU, Lissichkov T, Aldaoud A et al. (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27(26):4378–4384
Köhne CH, Folprecht G, Goldberg RM et al. (2008) Chemotherapy in elderly patients with colorectal cancer. Oncologist 13(4):390–402
Kudoh S, Takeda K, Nakagawa K et al. (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24(22):3657–3663
Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9(3):179–186
Lees J, Chan A. (2011) Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 12(13):1249–57
Lewis JH, Kilgore ML, Goldman DP et al. (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21(7):1383–1389
Lièvre A, Bachet JB, Boige V et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26(3):374–379
Lynch TJ, Bell DW, Sordella R et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139
Mahoney FI, Barthel DW (1965) Functional evaluation. Md State Med J 14:61–65
Mamounas EP, Jeong JH, Wickerham DL et al. (2008) Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. (2008) J Clin Oncol. 26(12):1965–71
Massie MJ (2004) Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr (32): 57–71 Tumorerkrankungen
Mateos MV, Oriol A, Martínez-López J et al. (2010) Bortezomib, melphalan and prednisone versus bortezomib, thalidomide and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 11(10):934–41
Miller K, Wang M, Gralow J et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676
Mor V, Laliberte L, Morris JN et al. (1984) The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 53(9):2002–2007
Muss HB, Berry DA, Cirrincione CT et al. (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360(20):2055–2065
Neugut AI, Fleischauer AT, Sundararajan V et al. (2002) Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol 20(11):2643–2650
Nikolaus T, Specht-Leible N, Bach M et al. (1994) Social aspects in diagnosis and therapy of very elderly patients. Initial experiences with a newly developed questionnaire within the scope of geriatric assessment. Z Gerontol 27(4):240–245
Osborne CK, Pippen J, Jones SE et al. (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20(16):3386–3395
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672
Pignon JP, Tribodet H, Scagliotti GV et al. (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26(21):3552–3559
Pinder MC, Duan Z, Goodwin JS et al. (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25(25):3808–3815
Podsiadlo D, Richardson S (1991) The timed „Up & Go“: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39(2):142–148
Quoix E, Zalcman G, Oster JP et al., Intergroupe Francophone de Cancérologie Thoracique (2011) Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 378(9796):1079–88
Rao AV, Hsieh F, Feussner JR et al. (2005) Geriatric evaluation and management units in the care of the frail elderly cancer patient. J Gerontol A Biol Sci Med Sci 60(6):798–803
Read WL, Tierney RM, Page NC et al. (2004) Differential prognostic impact of comorbidity. J Clin Oncol 22(15): 3099–3103
Rehse B, Pukrop R (2003) Effects of psychosocial interventions on quality of life in adult cancer patients: meta analysis of 37 published controlled outcome studies. Patient Educ Couns 50 (2):179–186 Tumorerkrankungen
Repetto L, Venturino A, Vercelli M et al. (1998) Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions (see comments). Cancer 82(4): 760–765
Repetto L, Biganzoli L, Koehne CH et al. (2003) EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39(16): 2264–2272
Romond EH, Perez EA, Bryant J et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (16): 1673–1684 Tumorerkrankungen
Sargent DJ, Goldberg RM, Jacobson SD et al. (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345(15):1091–1097
Sargent DJ, Wieand HS, Haller DG et al. (2005) data from 20,898 patients on 18 randomized trials. J Clin Oncol, 2005. 23(34):8664–8670
Sargent DJ, Köhne CH, Sanoff HK et al. (2009) Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol. 27(12):1948–55
Schairer C, Mink PJ, Carroll L et al. (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96(17):1311–1321
Schmiegel W, Pox C, Reinacher-Schick A et al.,Federal Committee of Physicians and Health Insurers (2010) S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol 48(1):65–136
Schröder KE, Schwarzer R (1997) Bewältigungsressourcen. In: C. Tesch-Römer, C. Salewski, G. Schwarz (Eds) Psychologie der Bewältigung. Psychologie, Weinheim, S. 174–195
Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792
Slamon D, Eiermann W, Robert N et al., Breast Cancer International Research Group (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 365(14):1273–83
Sommer G, Fydrich T (1989) Unterstützung: Diagnostik, Konzepte, F-SOZU. Tübingen, Deutsche Gesellschaft für Verhaltenstherapie
Statistisches Bundesamt, Wiesbaden 2013 https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Sterbefaelle/Tabellen/SterbetafelDeutschland.html. Gesehen 05.03.2013
Stein BN, Petrelli NJ, Douglass HO et al. (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 75(1):11–17
Strauß B, Berger U, Troschke J von et al. E (2004) Lehrbuch medizinische Psychologie und medizinische Soziologie. Hogrefe, Göttingen
Stuck AE, Siu AL, Wieland GD et al. (1993) Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 342 (8878): 1032–1036Tumorerkrankungen
Sundararajan V, Mitra N, Jacobson JS et al. (2002) Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136(5): 349–357
The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91(1):66–72
Tinetti ME (1986) Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc 34(2):119–126
Tol J, Koopman M, Cats A et al. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360 (6): 563–572 Tumorerkrankungen
Tournigand C, André T, Bonnetain F et al. (2012) Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial. J Clin Oncol. 30(27):3353–60
Turner NJ, Haward RA, Mulley GP et al. (1999) Cancer in old age – is it inadequately investigated and treated? BMJ 319(7205):309–312
Twelves C, Wong A, Nowacki MP et al. (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352(26):2696–2704
Wagner AD, Wedding U (2009) Advances in the pharmacological treatment of gastro-oesophageal cancer. Drugs Aging 26(8):627–646
Watson M, McCarron J, Law M (1992) Anticipatory nausea and emesis, and psychological morbidity: assessment of prevalence among out-patients on mild to moderate chemotherapy regimens. Br J Cancer 66(5):862–866
Watson YI, Arfken CL, Birge SJ (1993) Clock completion: an objective screening test for dementia. J Am Geriatr Soc 41(11):1235–1240
Wedding U, Höffken K, Friedrich C et al. (2007a) Health services research and geriatrics: deficits and research approaches using the example of colorectal carcinoma and anaemia. Z Arztl Fortbild Qualitatssich 101(9):587–592
Wedding U, Honecker F, Bokemeyer C et al. (2007b) Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 14(1):44–56
Wedding U, Honecker F, Pienkta L et al. (2007c) Klinische Studien und Patientenregister für alte Patienten mit Krebserkrankungen. Onkologe 13(9):783–791
Wedding U, Röhrig B, Pientka L et al. (2007d) Anaemia-related impairment in quality of life in elderly cancer patients prior to chemotherapy. J Cancer Res Clin Oncol 133(5):279–286
Wehling M (2008) Drug therapy in the elderly: too much or too little, what to do? A new assessment system: fit for the aged (FORTA). Dtsch Med Wochenschr 133 (44): 2289–2291 Tumorerkrankungen
Wehling M (2009) Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged. J Am Geriatr Soc 57(3):560–561
Wheatley-Price P, Ding K, Seymour L et al. (2008) Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26(14):2350–2357
Wildes TM, Vij R, Petersdorf SH et al. (2012) New treatment approaches for older adults with multiple myeloma. J Geriatr Oncol 3 (3): 279–290 Tumorerkrankungen
Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO (1982) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17(1):37–49
Zhou C, Wu YL, Chen G et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735–42
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wehling, M., Burkhardt, H., Schwarz, S., Frölich, L., Wedding, U. (2016). Spezielle Aspekte bezogen auf Organsysteme nach geriatrisch-klinischer Bedeutung. In: Wehling, M., Burkhardt, H. (eds) Arzneitherapie für Ältere. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48126-4_2
Download citation
DOI: https://doi.org/10.1007/978-3-662-48126-4_2
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-48125-7
Online ISBN: 978-3-662-48126-4
eBook Packages: Medicine (German Language)